Evidence map›Paper›PMID 41878451›Full record

ArticleFrontiers in immunology2026

Integrating chronic inflammation and hypoxia: the potential role of HIF-1α in tumor behavior and therapy response in high-grade serous ovarian cancer.

Sara Polajžer, David Lukanović, Erik Škof, Borut Kobal, Katarina Černe

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara PolajžerInstitute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
David LukanovićDepartment of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Erik ŠkofDepartment of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Borut KobalDepartment of Gynecology, Division of Gynecology and Obstetrics, Ljubljana University Medical Centre, Ljubljana, Slovenia.
Katarina ČerneInstitute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) is marked by late diagnosis and chemoresistance, partly driven by chronic inflammation and hypoxia in the tumor microenvironment. Hypoxia-inducible factor 1-alpha (HIF-1α) is a key regulator of these processes; however, its spatial distribution, interaction with inflammation, and effect on chemotherapy response in HGSOC remain unclear. This retrospective study included 28 advanced HGSOC patients treated with neoadjuvant chemotherapy (NACT). Samples were collected at primary surgery (PS) (ovarian and peritoneal tissue, plasma, ascites) and post-NACT at interval debulking surgery (IDS) (omentum, peritoneal tissue, plasma). HIF-1α mRNA expression varied by site, with higher levels in omental and peritoneal tissues compared to ovarian tissue. Plasma and ascites concentrations were significantly correlated, although the mean ascites concentration was lower. Elevated HIF-1α concentration in ascites and plasma at baseline correlated with ESR (erythrocyte sedimentation rate) >30 mm/h, which was also correlated with

Indexed as

Cystadenocarcinoma, SerousHypoxia-Inducible Factor 1, alpha SubunitInflammationOvarian NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm GradingRetrospective StudiesTumor MicroenvironmentHIF1A protein, humanHypoxia-Inducible Factor 1, alpha Subunitbody fluidschronic inflammationHIF-1αhigh-grade serous ovarian carcinomaneoadjuvant chemotherapytumor tissue

Identifiers

PMID41878451
PMCPMC13006265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.